How do biologics compare to targeted drugs for treating systemic lupus erythematosus?
Biologics and targeted small molecule drugs are two classes of advanced treatments for systemic lupus erythematosus (SLE). Biologics are large proteins made from living cells that target specific immune pathways, while targeted drugs are smaller molecules that can be taken orally and also block specific signals. A 2024 network meta-analysis compared many of these drugs head-to-head using data from 32 trials involving over 17,000 patients 4. The short answer: some targeted drugs, like telitacicept, appear more effective for overall disease control than older biologics like belimumab, but safety and side effects differ between drugs 411.
What the research says
A large network meta-analysis of 32 randomized controlled trials (17,121 patients) compared multiple biologics and targeted drugs for SLE 4. For the standard SRI-4 response (a measure of overall disease improvement), telitacicept (a targeted fusion protein) was superior to belimumab (a biologic), and ustekinumab (a biologic) outperformed epratuzumab (another biologic) 4. For skin symptoms (CLASI-50), deucravacitinib and anifrolumab were more effective than baricitinib 4. Upadacitinib (a targeted drug) showed better BICLA response and low disease activity (LLDAS) rates than baricitinib 4.
A separate meta-analysis focusing on belimumab versus anifrolumab found no significant difference in SRI-4 response between the two biologics for SLE, but anifrolumab was linked to more herpes zoster infections 8. Another meta-analysis comparing telitacicept and belimumab directly found that telitacicept significantly increased SRI-4 response rates (relative risk 2.03) and SRI-7 response rates (relative risk 3.61) compared to belimumab 11.
Safety also varies. The network meta-analysis reported that anifrolumab, iberdomide, and telitacicept were associated with higher rates of adverse events like upper respiratory infections, urinary tract infections, and herpes zoster 4. The belimumab-versus-anifrolumab meta-analysis confirmed a higher risk of herpes zoster with anifrolumab 8.
It is important to note that these comparisons are mostly indirect (not head-to-head trials), so results should be interpreted with caution. Your doctor can help weigh the benefits and risks for your specific situation.
What to ask your doctor
- Which biologic or targeted drug has the best evidence for my type of SLE symptoms (joints, skin, kidneys)?
- What are the specific side effect risks for each option, such as infections or shingles?
- How do the costs and insurance coverage compare between biologics and targeted oral drugs?
- Would a drug like telitacicept or anifrolumab be a good option for me based on recent meta-analyses?
- How will we monitor my response and adjust treatment if needed?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.